Novavax
Novavax
Novavax (pronounced: noh-vuh-vaks) is an American vaccine development company. It is focused on the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.
Etymology
The name "Novavax" is derived from the Latin words "nova" meaning "new", and "vax", a short form for "vaccine". Thus, the name implies a new approach to vaccines.
History
Novavax was founded in 1987 and is headquartered in Gaithersburg, Maryland. The company has been involved in the development of several vaccines for various diseases including respiratory syncytial virus (RSV), influenza, and the Ebola virus.
In 2020, Novavax received funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for the COVID-19 pandemic. The vaccine, known as NVX-CoV2373, has shown promising results in clinical trials.
Related Terms
- Vaccine: A biological preparation that provides active acquired immunity to a particular infectious disease.
- Respiratory syncytial virus (RSV): A virus that causes respiratory tract infections.
- Influenza: A viral infection that attacks your respiratory system.
- Ebola virus: A virus that causes severe bleeding, organ failure, and can lead to death.
- COVID-19: An infectious disease caused by a newly discovered coronavirus.
- Coalition for Epidemic Preparedness Innovations (CEPI): A foundation that takes donations from public, private, philanthropic, and civil society organisations, to finance independent research projects to develop vaccines against emerging infectious diseases.
External links
- Medical encyclopedia article on Novavax
- Wikipedia's article - Novavax
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski